Molecular Diagnostics Market to Grow with a CAGR of 7.10% through 2030
Boosting Prevalence of Chronic Ailments and Modernizing Healthcare Infrastructure are expected to drive the Global Molecular Diagnostics Market growth in the forecast period, 2026-2030
According to TechSci Research
report, “Molecular Diagnostics Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Molecular
Diagnostics Market stood at USD 17.65 Billion in 2024 and is anticipated to grow with a CAGR of 7.10% in the
forecast period.
Ongoing innovations in molecular diagnostic technologies such as real-time PCR, next-generation sequencing (NGS), microarrays, and CRISPR-based assays are significantly enhancing the sensitivity, speed, and scalability of diagnostic testing. These technological breakthroughs are enabling the transition of molecular diagnostics beyond traditional hospital laboratories to point-of-care settings and even home-based testing, thereby expanding market reach and accessibility.
Early detection is critical in improving patient outcomes and reducing long-term treatment costs. Molecular diagnostics deliver high sensitivity and specificity, allowing for the identification of diseases at an early stage. This capability is particularly valuable in oncology and infectious disease management, where prompt intervention can substantially improve prognosis and survival rates. The increasing proportion of elderly individuals worldwide is driving higher demand for molecular diagnostic solutions. Older adults are more vulnerable to chronic and infectious diseases, prompting healthcare systems to adopt efficient, non-invasive, and accurate diagnostic tools. This demographic trend is contributing to the steady growth of the molecular diagnostics market.
Significant capital inflows from government bodies, research institutions, and private investors are fueling advancements in molecular diagnostics. Especially post-COVID-19, there has been a marked increase in funding for research, infrastructure development, and disease surveillance programs. These investments are accelerating innovation and expanding the availability of molecular testing solutions across global markets. Regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) are adopting streamlined approval processes for molecular diagnostic products, particularly during public health emergencies. Mechanisms such as Emergency Use Authorizations (EUAs) have facilitated quicker market entry for innovative diagnostic solutions, fostering a more agile and responsive regulatory environment.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on "Global
Molecular Diagnostics Market”
Molecular Diagnostics
Market is segmented into product & service, technology, application, end
user, regional distribution, and company.
Based on technology, the Polymerase Chain Reaction (PCR) segment dominated the Global molecular diagnostics market. PCR is a foundational technology in molecular diagnostics, widely used across a range of applications including infectious disease detection, oncology, genetic disorder screening, and pharmacogenomics. Its versatility allows healthcare providers to detect pathogens, gene mutations, and other molecular markers with high specificity and sensitivity. This adaptability positions PCR as a preferred choice in both routine diagnostics and specialized testing.
PCR has firmly established itself as the gold standard for infectious disease diagnostics. Its ability to detect minute quantities of DNA or RNA makes it ideal for identifying viral and bacterial infections such as COVID-19, HIV, hepatitis, influenza, and tuberculosis. The COVID-19 pandemic, in particular, significantly accelerated global PCR usage, leading to major investments in infrastructure, equipment, and consumables related to PCR testing. The evolution of PCR into more advanced formats such as quantitative PCR (qPCR) and digital PCR (dPCR) has greatly enhanced the technology’s capabilities. These newer iterations provide higher accuracy, faster turnaround times, and the ability to quantify nucleic acids in real-time. Automation and integration into high-throughput platforms have further strengthened PCR’s position in clinical laboratories, hospitals, and point-of-care settings.
Based on region, The Asia Pacific region is positioned to witness the fastest growth in the global molecular diagnostics market, driven by a unique convergence of demographic, economic, technological, and policy-related factors. Asia Pacific accounts for the largest share of the global population, including a significant proportion of aging individuals who are more vulnerable to chronic and infectious diseases. Countries such as China, India, and Japan are experiencing rising incidences of cancer, tuberculosis, hepatitis, and genetic disorders, creating substantial demand for early and accurate diagnostic solutions. This rising disease burden is a major catalyst for molecular diagnostics adoption.
Governments across Asia Pacific are heavily investing in healthcare infrastructure to expand access to quality medical services. Initiatives such as Ayushman Bharat in India, Healthy China 2030, and Japan’s Health and Medical Strategy aim to strengthen public health systems and improve disease screening programs. These initiatives are leading to greater deployment of diagnostic technologies, including PCR, NGS, and point-of-care molecular testing across hospitals, labs, and rural healthcare centers.
Major companies operating in
Global Molecular Diagnostics Market are:
- F Hoffmann-la Roche Ltd
- Illumina Ltd
- Hologic Corporation
- Agilent Technologies Inc.
- Qiagen NV
- Grifols S.A.
- Becton, Dickinson and Company
- Abbott Laboratories, Inc.
- Biomerieux SA
- Bio-Rad Laboratories Inc.
- Sysmex Corporation
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“The Global Molecular Diagnostics market is undergoing a transformative growth phase, fueled by technological innovation, rising disease prevalence, increased emphasis on personalized medicine, and expanding global healthcare access. As demand intensifies for early, accurate, and rapid diagnostic solutions, molecular diagnostics is becoming a cornerstone of modern healthcare delivery. With continued advancements in PCR, sequencing, and point-of-care technologies, and strong growth momentum in emerging markets such as Asia Pacific, the market is well-positioned for sustained expansion. Strategic collaborations, increased investments, and supportive regulatory frameworks will further accelerate innovation and global adoption, making molecular diagnostics an indispensable tool in the future of preventive and precision medicine”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Products and Services (Reagents and Kits, Instruments, Services & Software), By Technology (Polymerase Chain Reaction (PCR), Sequencing, In-situ hybridization, Chips and microarrays, Mass spectrometry, Others), By Application (Infectious disease, Oncology testing, Genetic testing, Blood screening, Others), By End User (Hospitals, Academic & Reference Laboratories, Others), By Region & Competition, 2020-2030F”, has evaluated the future growth
potential of Global Molecular Diagnostics Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Molecular Diagnostics Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com